Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Darifenacin in Overactive Bladder
NCT00170755Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of darifenacin in overactive bladder syndrome (OAB), sponsored by Novartis. Started Apr 2002; status: completed.
02
Drugs
darifenacin
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT00170755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00170755.